Back to Search Start Over

Predicting treatment failure in stage III colon cancer patients after radical surgery.

Authors :
Zeng H
Zhong X
Liu W
Liang B
Xue X
Yu N
Xu D
Wang X
Lin S
Source :
Frontiers in oncology [Front Oncol] 2024 May 16; Vol. 14, pp. 1397468. Date of Electronic Publication: 2024 May 16 (Print Publication: 2024).
Publication Year :
2024

Abstract

Purpose: The aim to assess treatment failure in patients with stage III colon cancer who underwent radical surgery and was analyzed using the nomogram.<br />Methods: Clinical factors and survival outcomes for stage III colon cancer patients registered in the SEER database from 2018 to 2019 were analyzed, with patients split into training and testing cohorts (7:3 ratio). A total of 360 patients from the First Affiliated Hospital of Longyan served as an external validation cohort. Independent predictors of treatment failure were identified using logistic regression analyses. The nomograms was evaluated by concordance index (C-index), calibration curves, and the area under the curve (AUC), decision curve analysis (DCA) and clinical impact curves (CIC) assessed the clinical utility of nomograms versus TNM staging.<br />Results: The study included 4,115 patients with stage III colon cancer. Multivariate logistic analysis age, tumor site, pT stage, pN stage, chemotherapy, pretreatment CEA levels, number of harvested lymph nodes, perineural invasion and marital status were identified as independent risk factors for treatment failure. The C-indices for the training and testing sets were 0.853 and 0.841. Validation by ROC and calibration curves confirmed the stability and reliability of the model. DCA showed that the net clinical effect of the histogram was superior to that of the TNM staging system, while CIC highlighted the potentially large clinical impact of the model.<br />Conclusions: The developed Nomogram provides a powerful and accurate tool for clinicians to assess the risk of treatment failure after radical surgery in patients with stage III colon cancer.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2024 Zeng, Zhong, Liu, Liang, Xue, Yu, Xu, Wang and Lin.)

Details

Language :
English
ISSN :
2234-943X
Volume :
14
Database :
MEDLINE
Journal :
Frontiers in oncology
Publication Type :
Academic Journal
Accession number :
38817900
Full Text :
https://doi.org/10.3389/fonc.2024.1397468